UroGen Pharma (URGN) Reports In-Line Q1 EPS

UroGen Pharma (NASDAQ: URGN) reported Q1 EPS of ($1.30), in-line with the analyst estimate of ($1.30). Revenue for the quarter came in at $17.2 million versus the consensus estimate of $17.12 million.

For earnings history and earnings-related data on UroGen Pharma (URGN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Reading (RDI) Tops Q2 EPS by 4c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery